Immunogenicity of a chimeric hepatitis A virus (HAV) carrying the HIV gp41 epitope 2F5

Yuri Y. Kusov; Natalja A. Zamjatina; Valentina F. Poleschuk; Michail I. Michailov; Graziella Morace; Josef Eberle; Verena Gauss-Müller

doi:10.1016/j.antiviral.2006.08.003

Immunogenicity of a chimeric hepatitis A virus (HAV) carrying the HIV gp41 epitope 2F5

Yuri Y. Kusov^*, Natalja A. Zamjatina, Valentina F. Poleschuk, Michail I. Michailov, Graziella Morace, Josef Eberle, Verena Gauss-Müller

^*Corresponding author for this work

Institute of Virology and Cell Biology

19 Citations (Scopus)

Abstract

Its stable particle structure combined with its high immunogenicity makes the hepatitis A virus (HAV) a perfect carrier to expose foreign epitopes to the host immune system. In an earlier report [Beneduce, F., Kusov, Y., Klinger, M., Gauss-Müller, V., Morace, G., 2002. Chimeric hepatitis A virus particles presenting a foreign epitope (HIV gp41) at their surface. Antiviral Res. 55, 369-377] chimeric virus-like particles (HAV-gp41) were described that carried at their surface the dominant gp41 epitope 2F5 (2F5e) of the human immunodeficiency virus HIV-1. Extending this work, we now report that chimeric virus HAV-gp41 replicates in HAV-susceptible cells as well as in non-human primates. Infected marmosets developed both an anti-HAV and anti-2F5 epitope immune response. Furthermore, an HIV-neutralizing antibody response was elicited in guinea pigs immunized with HAV-gp41 chimeric particles. The results demonstrate that the replication-competent chimeric HAV-gp41 can serve as either a live or a subunit vaccine for eliciting of antibodies directed against a foreign antigenic epitope.

Original language	English
Journal	Antiviral Research
Volume	73
Issue number	2
Pages (from-to)	101-111
Number of pages	11
ISSN	0166-3542
DOIs	https://doi.org/10.1016/j.antiviral.2006.08.003
Publication status	Published - 02.2007

Funding

The authors are thankful to Ms. B. Andresen, Ms. S. Rasi, and Ms. M. Sbattella for excellent technical assistance and to Dr. G. Dzagurov for his help in virus particle preparation. Dr. G. Stiegler provided the monoclonal antibody 2F5 and the synthetic peptide, Dr. Luhm and Ms. Thiessen the INNO-LIA test. The financial support of the Deutsche Forschungsgemeinschaft (Sonderforschungsbereich 367, project B7) is acknowledged.

Research Areas and Centers

Academic Focus: Center for Infection and Inflammation Research (ZIEL)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.antiviral.2006.08.003

Cite this

@article{a0560513fdc84e89b630da2eb9036d10,

title = "Immunogenicity of a chimeric hepatitis A virus (HAV) carrying the HIV gp41 epitope 2F5",

abstract = "Its stable particle structure combined with its high immunogenicity makes the hepatitis A virus (HAV) a perfect carrier to expose foreign epitopes to the host immune system. In an earlier report [Beneduce, F., Kusov, Y., Klinger, M., Gauss-M{\"u}ller, V., Morace, G., 2002. Chimeric hepatitis A virus particles presenting a foreign epitope (HIV gp41) at their surface. Antiviral Res. 55, 369-377] chimeric virus-like particles (HAV-gp41) were described that carried at their surface the dominant gp41 epitope 2F5 (2F5e) of the human immunodeficiency virus HIV-1. Extending this work, we now report that chimeric virus HAV-gp41 replicates in HAV-susceptible cells as well as in non-human primates. Infected marmosets developed both an anti-HAV and anti-2F5 epitope immune response. Furthermore, an HIV-neutralizing antibody response was elicited in guinea pigs immunized with HAV-gp41 chimeric particles. The results demonstrate that the replication-competent chimeric HAV-gp41 can serve as either a live or a subunit vaccine for eliciting of antibodies directed against a foreign antigenic epitope.",

author = "Kusov, \{Yuri Y.\} and Zamjatina, \{Natalja A.\} and Poleschuk, \{Valentina F.\} and Michailov, \{Michail I.\} and Graziella Morace and Josef Eberle and Verena Gauss-M{\"u}ller",

year = "2007",

month = feb,

doi = "10.1016/j.antiviral.2006.08.003",

language = "English",

volume = "73",

pages = "101--111",

journal = "Antiviral Research",

issn = "0166-3542",

publisher = "Elsevier B.V.",

number = "2",

}

TY - JOUR

T1 - Immunogenicity of a chimeric hepatitis A virus (HAV) carrying the HIV gp41 epitope 2F5

AU - Kusov, Yuri Y.

AU - Zamjatina, Natalja A.

AU - Poleschuk, Valentina F.

AU - Michailov, Michail I.

AU - Morace, Graziella

AU - Eberle, Josef

AU - Gauss-Müller, Verena

PY - 2007/2

Y1 - 2007/2

N2 - Its stable particle structure combined with its high immunogenicity makes the hepatitis A virus (HAV) a perfect carrier to expose foreign epitopes to the host immune system. In an earlier report [Beneduce, F., Kusov, Y., Klinger, M., Gauss-Müller, V., Morace, G., 2002. Chimeric hepatitis A virus particles presenting a foreign epitope (HIV gp41) at their surface. Antiviral Res. 55, 369-377] chimeric virus-like particles (HAV-gp41) were described that carried at their surface the dominant gp41 epitope 2F5 (2F5e) of the human immunodeficiency virus HIV-1. Extending this work, we now report that chimeric virus HAV-gp41 replicates in HAV-susceptible cells as well as in non-human primates. Infected marmosets developed both an anti-HAV and anti-2F5 epitope immune response. Furthermore, an HIV-neutralizing antibody response was elicited in guinea pigs immunized with HAV-gp41 chimeric particles. The results demonstrate that the replication-competent chimeric HAV-gp41 can serve as either a live or a subunit vaccine for eliciting of antibodies directed against a foreign antigenic epitope.

AB - Its stable particle structure combined with its high immunogenicity makes the hepatitis A virus (HAV) a perfect carrier to expose foreign epitopes to the host immune system. In an earlier report [Beneduce, F., Kusov, Y., Klinger, M., Gauss-Müller, V., Morace, G., 2002. Chimeric hepatitis A virus particles presenting a foreign epitope (HIV gp41) at their surface. Antiviral Res. 55, 369-377] chimeric virus-like particles (HAV-gp41) were described that carried at their surface the dominant gp41 epitope 2F5 (2F5e) of the human immunodeficiency virus HIV-1. Extending this work, we now report that chimeric virus HAV-gp41 replicates in HAV-susceptible cells as well as in non-human primates. Infected marmosets developed both an anti-HAV and anti-2F5 epitope immune response. Furthermore, an HIV-neutralizing antibody response was elicited in guinea pigs immunized with HAV-gp41 chimeric particles. The results demonstrate that the replication-competent chimeric HAV-gp41 can serve as either a live or a subunit vaccine for eliciting of antibodies directed against a foreign antigenic epitope.

UR - https://www.scopus.com/pages/publications/33846343262

U2 - 10.1016/j.antiviral.2006.08.003

DO - 10.1016/j.antiviral.2006.08.003

M3 - Journal articles

C2 - 17014915

AN - SCOPUS:33846343262

SN - 0166-3542

VL - 73

SP - 101

EP - 111

JO - Antiviral Research

JF - Antiviral Research

IS - 2

ER -

Immunogenicity of a chimeric hepatitis A virus (HAV) carrying the HIV gp41 epitope 2F5

Abstract

Funding

Research Areas and Centers

UN SDGs

Access to Document

Other files and links

Fingerprint

The switch from translation to replication in the life cycle of the hepatitis A virus (HAV): A cell-virus interplay

Cite this

Immunogenicity of a chimeric hepatitis A virus (HAV) carrying the HIV gp41 epitope 2F5

Abstract

Funding

Research Areas and Centers

UN SDGs

Access to Document

Other files and links

Fingerprint

Projects

The switch from translation to replication in the life cycle of the hepatitis A virus (HAV): A cell-virus interplay

Cite this